KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBIT Margin (2019 - 2026)

Esperion Therapeutics filings provide 7 years of EBIT Margin readings, the most recent being 50.6% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 5699.0% to 50.6% in Q4 2025 year-over-year; TTM through Dec 2025 was 14.95%, a 142.0% decrease, with the full-year FY2025 number at 14.95%, down 142.0% from a year prior.
  • EBIT Margin hit 50.6% in Q4 2025 for Esperion Therapeutics, up from 11.41% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 52.47% in Q1 2024 to a low of 1038.15% in Q1 2021.
  • Median EBIT Margin over the past 5 years was 106.21% (2023), compared with a mean of 167.06%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 300782bps in 2021 and later crashed -19798bps in 2022.
  • Esperion Therapeutics' EBIT Margin stood at 361.2% in 2021, then soared by 37bps to 225.92% in 2022, then soared by 42bps to 131.37% in 2023, then soared by 95bps to 6.4% in 2024, then skyrocketed by 891bps to 50.6% in 2025.
  • The last three reported values for EBIT Margin were 50.6% (Q4 2025), 11.41% (Q3 2025), and 8.61% (Q2 2025) per Business Quant data.